From innovation to access: securing the last mile in rare disease
Why do approved rare disease therapies still struggle to reach European patients?
Bringing a rare disease therapy to market is only one of the first challenges after approval. Across Europe’s more than 27 healthcare systems, biotech companies face complex regulatory pathways, diverse HTA requirements and operational barriers that delay patient access, even after approval.
This white paper explores the potential barriers between regulatory approval and real-word patient access and the strategic solutions proven to work.
Download to discover:
- Operational bottlenecks slowing therapy delivery across Europe
- Why clinical evidence fails to secure reimbursement and what payers actually need
- How innovative trial designs and stakeholder engagement accelerate access
- The role of real-world evidence in proving therapy value to payers
- Practical frameworks for building commercial strategies across 27+ markets
Download your free copy and close the gap between innovation and access.
About Sciensus
Sciensus is the UK’s leading provider of complex clinical care at home. For over 30 years, we have partnered with the NHS to deliver specialist medicines, clinical nursing and patient support to people living with cancer, rare diseases and complex long-term conditions – supporting more than 300,000 patients a year across 180+ NHS trusts.
Beyond the UK, Sciensus helps pharmaceutical and biotech companies reach patients across Europe, managing the regulatory, logistics and patient support complexity of launching medicines in multiple markets.